Advancements in combining targeted therapy and immunotherapy for colorectal cancer.

IF 14.3 1区 医学 Q1 ONCOLOGY Trends in cancer Pub Date : 2024-07-01 Epub Date: 2024-05-31 DOI:10.1016/j.trecan.2024.05.001
Manisha Singh, Van Karlyle Morris, Irfan N Bandey, David S Hong, Scott Kopetz
{"title":"Advancements in combining targeted therapy and immunotherapy for colorectal cancer.","authors":"Manisha Singh, Van Karlyle Morris, Irfan N Bandey, David S Hong, Scott Kopetz","doi":"10.1016/j.trecan.2024.05.001","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a prevalent gastrointestinal cancer posing significant clinical challenges. CRC management traditionally involves surgery, often coupled with chemotherapy. However, unresectable or metastatic CRC (mCRC) presents a complex challenge necessitating innovative treatment strategies. Targeted therapies have emerged as the cornerstone of treatment in such cases, with interventions tailored to specific molecular attributes. Concurrently, immunotherapies have revolutionized cancer treatment by harnessing the immune system to combat malignant cells. This review explores the evolving landscape of CRC treatment, focusing on the synergy between immunotherapies and targeted therapies, thereby offering new avenues for enhancing the effectiveness of therapy for CRC.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":14.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.05.001","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer (CRC) is a prevalent gastrointestinal cancer posing significant clinical challenges. CRC management traditionally involves surgery, often coupled with chemotherapy. However, unresectable or metastatic CRC (mCRC) presents a complex challenge necessitating innovative treatment strategies. Targeted therapies have emerged as the cornerstone of treatment in such cases, with interventions tailored to specific molecular attributes. Concurrently, immunotherapies have revolutionized cancer treatment by harnessing the immune system to combat malignant cells. This review explores the evolving landscape of CRC treatment, focusing on the synergy between immunotherapies and targeted therapies, thereby offering new avenues for enhancing the effectiveness of therapy for CRC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
结直肠癌靶向治疗与免疫疗法相结合的进展。
结肠直肠癌(CRC)是一种常见的胃肠道癌症,给临床带来了巨大挑战。传统的 CRC 治疗包括外科手术,通常还辅以化疗。然而,无法切除或转移的 CRC(mCRC)是一项复杂的挑战,需要创新的治疗策略。靶向疗法已成为此类病例的治疗基石,可针对特定分子属性进行干预。与此同时,免疫疗法通过利用免疫系统对抗恶性细胞,彻底改变了癌症治疗。本综述探讨了 CRC 治疗不断发展的前景,重点关注免疫疗法和靶向疗法之间的协同作用,从而为提高 CRC 治疗的有效性提供新的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Trends in cancer
Trends in cancer Medicine-Oncology
CiteScore
28.50
自引率
0.50%
发文量
138
期刊介绍: Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.
期刊最新文献
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence. The UPRising connection between endoplasmic reticulum stress and the tumor microenvironment. Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology. A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition. Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1